FrancophonIA/ELRC3.0 huggingface dataset:
English: Capsule shells contain gelatin, titanium dioxide E171; ink contains iron oxide E172.
Lithuanian: Kapsuleje yra želatinos, titano dioksido E171; dažuose yra geležies oksido E172.
English: Active peptic ulceration or gastrointestinal (GI) bleeding.
Lithuanian: Aktyvi pepsine opa arba kraujavimas iš virškinimo trakto (VT).
English: Therefore, this SPC may not necessarily represent the current text.
Lithuanian: Todel ši Preparato charakteristiku santrauka nebutinai atitinka dabartini teksta.
English: Women who take celecoxib should not breastfeed.
Lithuanian: Moterims, kurios vartoja celekoksiba, žindyti negalima.
English: Although it is not a strong inhibitor of this enzyme, a dose reduction may be necessary for individually dose-titrated drugs that are metabolised by CYP2D6 (See 4.5).
Lithuanian: Nors toks poveikis nestiprus, taciau kartais gali tekti mažinti kai kuriu kartu vartojamu preparatu, kuriuos metabolizuoja CYP2D6, doze (žr. 4.5 skyriu).
English: In vitro studies have shown some potential for celecoxib to inhibit CYP2C19 catalysed metabolism.
Lithuanian: Tyrimais in vitro nustatyta, kad celekoksibas silpnai slopina CYP2C19 katalizuojama metabolizma.
English: In an interaction study, celecoxib had no clinically relevant effects on the pharmacokinetics of oral contraceptives (1 mg norethistherone /35 microg ethinylestradiol).
Lithuanian: Saveikos tyrimu duomenimis, celekoksibas nesukele klinikai reikšmingu geriamuju kontraceptiku farmakokinetikos pokyciu (1 mg noretisterono/35 µg etinilestradiolio).
English: Patients should be adequately hydrated and consideration should be given to monitoring of renal function after initiation of concomitant therapy, and periodically thereafter.
Lithuanian: Pacientas turi vartoti pakankamai skysciu, butina nuolatos stebeti jo inkstu funkcija pradejus kartu vartoti minetus preparatus ir reguliariai tikrinti tesiant gydyma.
English: Czech Republic
Lithuanian: Cekijos Respublika
English: Based on conventional studies, genotoxicity or carcinogenicity, no special hazard for humans was observed, beyond those addressed in other sections of the SmPC.
Lithuanian: Remiantis iprastiniais kartotiniu doziu toksinio, genotoksinio arba kancerogeninio poveikio tyrimu duomenimis, kitokio žmogui žalingo poveikio nenustatyta, išskyrus ta, kuris aprašytas kituose preparato charakteristiku santraukos skyriuose.
English: The plasma concentration of celecoxib is approximately 100% increased in elderly women (>65 years).
Lithuanian: Senyvu moteru (>65 metu) kraujo plazmoje susidaro maždaug 100% didesne celekoksibo koncentracija.
English: Celecoxib inhibits CYP2D6.
Lithuanian: Celekoksibas slopina CYP2D6.
English: Celecoxib, as with other drugs inhibiting prostaglandin synthesis, may cause uterine inertia and premature closure of the ductus arteriosus during the last trimester.
Lithuanian: Celekoksibas, kaip ir kiti prostaglandinu sinteze slopinantys preparatai, gali sukelti gimdos inercija ir priešlaikini arterinio latako užakima trecia neštumo trimestre.
English: The data were inconsistent in comparison with diclofenac (150 mg per day).
Lithuanian: Celekoksibo ir diklofenako (150 mg per para) lyginamieji duomenys prieštaringi.
English: This USR was initiated on 16 February 2005 and finalised on 17 February 2005.
Lithuanian: sausio 18 d., vasario 15 d., ir gegužes 25 d.
English: The phase I metabolism is mainly catalysed by CYP2C9.
Lithuanian: Pirmosios fazes metu daugiausia preparato metabolizuojama, dalyvaujant CYP2C9.
English: Less than 1% of the population are poor metabolisers and have an enzyme with decreased activity.
Lithuanian: Mažiau kaip 1% žmoniu organizme preparatas metabolizuojamas silpnai del mažo fermento aktyvumo.
English: Celecoxib may mask fever and other signs of inflammation.
Lithuanian: Celekoksibas gali slepti karšciavima ir kitus uždegimo požymius.
English: History of hypersensitivity to the active substance or to any of the excipients (see 6.1).
Lithuanian: Padidejes jautrumas veikliajai arba bet kuriai pagalbinei preparato medžiagai (žr.
English: COX-2 has been identified in tissue around gastric ulcers in man but its relevance to ulcer healing has not been established.
Lithuanian: COX-2 nustatyta audiniuose aplink žmogaus skrandžio opa, taciau neirodyta, kad ji skatintu opos gijima.
English: Caution is also required in patients taking diuretic treatment or otherwise at risk of hypovolaemia.
Lithuanian: Taip pat rekomenduojama atsargiai celekoksibu gydyti pacientus, kurie vartoja diuretiku, bei tuos, kuriems del kokiu nors priežasciu gresia hipovolemija.
English: Capsule shells contain gelatin, titanium dioxide E171; ink contains indigotine E132
Lithuanian: Kapsuleje yra želatinos, titano dioksido E171; dažuose yra indigotino E132.
English: Ongoing Clinical Trials: Preliminary safety information from three long-term studies involving patients with Sporadic Adenomatous Polyps or who were predisposed to developing Alzheimer's disease treated with celecoxib is available.
Lithuanian: Gauti išankstiniai duomenys triju tebevykstanciu ilgalaikiu celekoksibo saugumo klinikiniu tyrimu, kuriuose dalyvauja ligoniai, turintys pavieniu storosios žarnos adenomatoziniu polipu arba predispozicija susirgti Alzheimerio liga.
English: Several clinical studies have been performed confirming efficacy and safety in osteoarthritis and rheumatoid arthritis.
Lithuanian: Atlikti keli klinikiniai celekoksibo efektyvumo ir saugumo tyrimai, kuriu metu buvo gydomi osteoartritu ir reumatoidiniu artritu sergantys pacientai.
English: 10 DATE OF REVISION OF THE TEXT
Lithuanian: TEKSTO PERŽIUROS DATA
English: Plasma protein binding is about 97% at therapeutic plasma concentrations and the drug is not preferentially bound to erythrocytes.
Lithuanian: Kai kraujo plazmoje susidaro gydomoji celekoksibo koncentracija, apie 97% preparato jungiasi su plazmos baltymais, bet nesijungia su eritrocitais.
English: Concomitant use of 200 mg single dose of celecoxib and 200 mg once daily of fluconazole, a potent CYP2C9 inhibitor, resulted in a mean increase in celecoxib Cmax of 60% and in AUC of 130%.
Lithuanian: Vartojant vienkartine 200 mg celekoksibo doze kartu su stipriu CYP2C9 inhibitoriumi flukonazoliu (200 mg viena karta per para), celekoksibo Cmax padidejo 60%, o AUC - 130%.
English: 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 100 mg or 200 mg celecoxib.
Lithuanian: KOKYBINE IR KIEKYBINE SUDETIS 100 mg kapsuleje yra 100 mg celekoksibo.
English: For all strokes, there was no increased event rate with celecoxib compared with placebo.
Lithuanian: Visu insultu atvejai, vartojant celekoksiba, nebuvo dažnesni nei vartojant placeba.
English: Ketoconazole or antacids have not been observed to affect the pharmacokinetics of celecoxib.
Lithuanian: Nustatyta, kad ketokonazolis ar antacidiniai preparatai neveikia celekoksibo farmakokinetikos.
English: GROUNDS FOR THE AMENDMENT OF THE MARKETING AUTHORISATION
Lithuanian: REGISTRAVIMO LIUDIJIMO PATAISU PAGRINDIMAS
English: Whereas, the CHMP - is of the Opinion that the benefit/risk balance of medicinal products containing celecoxib in the agreed indications remains favourable and the Marketing Authorisations should be maintained according to revised Summaries of Product Characteristics (attached in Annex III of the CHMP Opinion), - concluded that the cardiovascular safety and serious skin reactions should be continuously and carefully monitored and assessed, - recommended to initiate a long term study to investigate the safety of celecoxib relative to non selective NSAIDs.
Lithuanian: Kadangi CHMP - laikosi nuomones, kad vaistiniu preparatu, kuriu sudetyje yra celekoksibo, naudos irpavojaus santykis išlieka teigiamas patvirtintose indikacijose, o registravimo liudijimai ir toliau turi likti galioti atsižvelgiant i patikslintas Preparato charakteristiku santraukas (pridedamas CHMP nuomones III priede), - todel nusprende, kad preparato saugumas širdies ir kraujagysliu sistemai bei sunkios odos reakcijos turi buti nuolat kruopšciai stebimos ir vertinamos,
English: To continue to report all ADR frequencies, based on the adverse reaction profile derived from placebo controlled studies, particularly the long-term studies as well as other post marketing experience and make changes to the SPC in accordance with standard Pharmacovigilance reporting and procedures (PSUR, Type II variation within MRP).
Lithuanian: 4 klinikinis aspektas Toliau teikti informacija apie bet kokiu nepageidaujamu reakciju i vaista dažnuma, remiantis nepageidaujamu reakciju aprašu, gautu vykdant placebu kontroliuojamus tyrimus, ypac ilgalaikius tyrimus, bei remiantis kita poregistracine patirtimi, bei keisti preparato charakteristiku santrauka pagal standartinius farmacinio budrumo ataskaitu teikimo reikalavimus ir proceduras (PSUR, MRP II tipo keitimas).
English: Patients who experience dizziness, vertigo or somnolence while taking celecoxib should refrain from driving or operating machinery.
Lithuanian: Pacientams, kuriems pavartojus celekoksibo, sukasi ar svaigsta galva bei apima mieguistumas, vairuoti ir valdyti mechanizmu negalima.
English: The incidence of clinically significant decreases in haemoglobin (>2 g/dL), confirmed by repeat testing, was significantly lower in patients on celecoxib compared to the NSAID group, relative risk 0.29, 95% CI 0.17- 0.48.
Lithuanian: Kartojant hemoglobino koncentracijos tyrima nustatyta, kad pacientams, kurie vartojo celekoksiba, kliniškai reikšmingai hemoglobino koncentracija sumažejo (>2 g/dl) reciau nei NVNU vartojusiuju grupeje (santykine rizika - 0,29, 95% PI 0,17-0,48).
English: Pharmacotherapeutic group: ATC code: M01AH01.
Lithuanian: ATC kodas - MO1AH01.
English: oC.
Lithuanian: E.
English: Caution is advised with treatment of patients most at risk of developing a gastrointestinal complication with NSAIDs; the elderly, patients using any other NSAID or acetylsalicylic acid concomitantly or patients with a prior history of gastrointestinal disease, such as ulceration and GI bleeding.
Lithuanian: Rekomenduojama atsargiai preparatu gydyti pacientus, kuriems vartojant NVNU gresia didesnis virškinimo trakto komplikaciju pavojus: senyviems žmonems, vartojantiems kartu kitu NVNU arba acetilsalicilo rugšti arba pacientams, kurie anksciau sirgo virškinimo trakto liga, pavyzdžiui, opalige arba VT kraujavimais.
English: For the primary endpoint complicated ulcers (defined as gastrointestinal bleeding, perforation or obstruction) celecoxib was not significantly different than either ibuprofen or diclofenac individually.
Lithuanian: Pirminis ivertis rodo, kad opu komplikaciju (kraujavimas iš virškinimo trakto, perforacija ar nepraeinamumas) dažnumas celekoksibo, ibuprofeno ir diklofenako grupese skyresi statistiškai nereikšmingai.
English: § Further to the assessment of: - the new data provided on rofecoxib by the APPROVe clinical study, which revealed a risk of thrombotic CV events, - the data on celecoxib presented in the APC study, which suggested a dose-related increased risk of serious CV events, - the data on valdecoxib and parecoxib presented in the CABG (Coronary Artery Bypass Graft) and in the CABG II studies, which showed a higher rate of serious CV thromboembolic events in the parecoxib/valdecoxib treatment arm compared to the group of patients receiving placebo, - the data on etoricoxib in the EDGE study and pooled analyses of other clinical trials, which suggested an association with a higher thrombotic risk than naproxen, - the data on lumiracoxib in the Target study, which suggested a small increase in thrombotic events (especially myocardial infarction) versus naproxen, all available data show an increased risk of CV adverse reactions for Cox-2 inhibitors as a class and agreed that there is an association between duration and dose of intake and the probability of suffering a CV reaction.
Lithuanian: § ivertinus: - APPROVe klinikiniu tyrimu naujus duomenis apie rofekoksiba, kurie atskleidžia tromboziniu širdies ir kraujagysliu sutrikimu rizika, - APC tyrimo metu pateiktus duomenis apie celekoksiba, kurie leidžia manyti, jog padidejusi sunkiu širdies ir kraujagysliu sutrikimu rizika yra susijusi su doze, - CABG (vainikines arterijos jungties operacijos) ir CABG II tyrimu metu pateiktus valdekoksibo ir parekoksibo duomenis, kurie parode didesni širdies ir kraujagysliu tromboemoliniu sutrikimu dažni gydymo parekoksibu ir valdekoksibu grupeje, lyginant ji su pacientu, kurie gavo placeba, grupe, - EDGE tyrimo metu gautus ir analizuojant kitu klinikiniu tyrimu sukauptus etorikoksibo duomenis, kurie leidžia manyti, jog jis sukelia didesne tromboziu rizika negu naproksenas, - Target tyrimo metu gautus lumirakoksibo duomenis, kurie leidžia manyti, jog nežymiai padideja tromboziniu sutrikimu (ypac miokardo infarkto) atveju, lyginant su naproksenu,
English: The difference in antiplatelet activity between some COX-1 inhibiting NSAIDs and COX-2 selective inhibitors may be of clinical significance in patients at risk of thrombo-embolic reactions.
Lithuanian: Skirtingas NVNU slopinanciu COX-1 ir selektyviuju COX-2 inhibitoriu poveikis trombocitu funkcijai gali buti kliniškai reikšmingas tais atvejais, kai yra trombemboliniu komplikaciju pavojus.
English: These data resulted in the worldwide withdrawal of Vioxx (rofecoxib) from the market on 30 September 2004 by the MAH and raised questions regarding the cardiovascular safety of other Cox-2 inhibitors.
Lithuanian: RLT visame pasaulyje iš rinkos išeme Vioxx (rofekoksiba) ir iškele kitu Cox-2 inhibitoriu saugumo klausima širdies ir kraujagysliu atžvilgiu.
English: Further to discussions at the CHMP October 2004 plenary meeting, the European Commission recommended that this public health issue on all aspects of cardiovascular safety including thrombotic events and cardio-renal events is the subject of Community referrals under Article 31 of Directive 2001/83/EC, as amended regarding decentrally authorised products containing celecoxib, etoricoxib and lumiracoxib and subject to a review procedure under Article 18 of Council Regulation (EEC) No 2309/93, as amended regarding the centrally authorised products containing celecoxib (Onsenal), parecoxib (Dynastat/Rayzon) and valdecoxib (Bextra/Valdyn), which were started in November 2004.
Lithuanian: spalio men., Europos Komisija pateike rekomendavo šiam visuomenes sveikatos klausimui spresti visais širdies ir kraujagysliu sutrikimu aspektais, iskaitant trombozinius bei širdies ir inkstu sutrikimus, Bendrijos kreipimosi procedura, remiantis direktyvos 2001/83/EB su pakeitimais del decentralizuotu budu registruotu vaistu, kuriu sudetyje yra celekoksibo, etorikoksibo ir lumirakoksibo, 31 straipsniu, ir peržiurejimo procedura, remiantisTarybos reglamento (EEB) Nr.
English: Plasma concentrations of celecoxib are probably markedly increased in such patients.
Lithuanian: Tokiu pacientu kraujo plazmoje susidaro daug didesne celekoksibo koncentracija.
English: Cyclooxygenase is responsible for generation of prostaglandins.
Lithuanian: Ciklooksigenaze skatina prostaglandinu sinteze.
English: Celecoxib should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity.
Lithuanian: Reikia nutraukti celekoksibo vartojima, vos tik pasireiškus pirmiesiems odos išberimo, gleivines pažeidimo ar kitiems padidejusio jautrumo požymiams.
English: {INVENTED NAME, see Annex I } 200 mg capsule, hard.
Lithuanian: {Sugalvotas pavadinimas} 200 mg kietos kapsules.
English: Those patients on celecoxib and concomitant lowdose acetylsalicylic acid experienced 4 fold higher rates of complicated ulcers as compared to those on celecoxib alone.
Lithuanian: Tiems pacientams, kurie vartojo celekoksiba kartu su maža acetilsalicilo doze, opu komplikaciju buvo 4 kartus dažniau nei vartojusiesiems vien celekoksiba.
English: In the event of suspected overdose, appropriate supportive medical care should be provided e.g. by eliminating the gastric contents, clinical supervision and, if necessary, the institution of symptomatic treatment.
Lithuanian: Itarus perdozavima, skiriamos palaikomosios priemones, pavyzdžiui, plaunamas skrandis, stebima organizmo bukle ir, jeigu reikia, skiriamas simptominis gydymas.
English: COX-2 selective inhibitors are not a substitute for acetylsalicylic acid for prophylaxis of cardiovascular thrombo-embolic diseases because of their lack of antiplatelet effects.
Lithuanian: Selektyvuju COX-2 inhibitoriu netinka vartoti vietoj acetilsalicilo rugšties širdies ir kraujagysliu trombemboliniu ligu profilaktikai, nes jie neveikia trombocitu funkcijos.
English: Patients known to be CYP2C9 poor metabolisers should be treated with caution (see 5.2.
Lithuanian: Pacientus, kuriu organizme CYP2D9 metabolizuoja silpnai, gydyti preparatu reikia atsargiai (žr.
English: Coadministration of NSAIDs and cyclosporin or tacrolimus have been suggested to increase the nephrotoxic effect of cyclosporin and tacrolimus.
Lithuanian: Vartojant NVNU kartu su ciklosporinu arba takrolimusu, dideja nefrotoksinis ciklosporino ir takrolimuso poveikis.
English: 8 MARKETING AUTHORISATION NUMBER(S) [Item to be completed by the Marketing Authorisation Holder once the Marketing Authorisation has been granted.]
Lithuanian: REGISTRAVIMO LIUDIJIMO NUMERIS [Irašys registravimo liudijimo turetojas po preparato registracijos.
English: Rare: alopecia, photosensitivity
Lithuanian: Reti: alopecija, padidejes jautrumas šviesai.
English: Slovenia
Lithuanian: Slovenija
English: The CHMP agreed that an Urgent Safety Restriction (USR) on cardiovascular safety was needed to introduce new contraindications and strengthen warnings and information on side effects in the SPC.
Lithuanian: CHMP sutiko, jog, siekiant pateikti i Preparato charakteristiku santraukoje (PCS) naujas kotraindikacijas ir sugriežtinti ispejimus ir informacija apie šalutini poveiki, butinas skubus apribojimas širdies ir kraujagysliu saugumo sumetimais (USR).
English: To provide all ongoing epidemiological studies in accordance with updates on on-going post marketing activities (for example, within PSURs for Celebra).
Lithuanian: 5 klinikinis aspektas Suteikti visiems šiuo metu atliekamiems epidemiologiniams tyrimams naujausia informacija apie vykdoma poregistracine veikla (pavyzdžiui, PSUR Celebra vaistui).
English: *In a pooled analysis of 20 placebo-controlled studies with duration greater than 2 weeks up to 1 year in patients with OA and RA, the excess rate of myocardial infarction in patients treated with celecoxib 200 or 400 mg daily over placebo was 0.7 events per 1000 patients (Rare) and there was no excess of strokes.
Lithuanian: * 20 placebu kontroliuojamuju tyrimu, kuriuose dalyvavo osteoartritu ir reumatoidiniu artritu sergantys ligoniai, jungtines analizes duomenimis, ilgiau kaip 2 savaites ar iki vieneriu metu gydant 200-400 mg celekoksibo doze 1000 ligoniu teko 0,7 nepageidaujamu reiškiniu atveju daugiau (retai) nei vartojant placeba, o insulto perviršio nebuvo.
English: Therefore, patients receiving oral anticoagulants should be closely monitored for their prothrombin time INR, particularly in the first few days when therapy with celecoxib is initiated or the dose of celecoxib is changed (see 4.4).
Lithuanian: Pacientams, vartojantiems geriamuju antikoaguliantu, reikia atidžiai tirti protrombino laika INR, ypac pirmosiomis celekoksibo vartojimo dienomis ir keiciant celekoksibo doze (žr.
English: For excipients, see 6.1.
Lithuanian: Pagalbines medžiagos išvardytos 6.1 skyriuje.
English: No statistically significant inhibition of COX-1 (assessed as ex vivo inhibition of thromboxane B2 [TxB2] formation) was observed in this dose range in healthy volunteers.
Lithuanian: Sveikiems savanoriams tokios preparato dozes statistiškai reikšmingai neslopino COX-1 (tirtas tromboksano B2 [TxB2] sintezes slopinimas ex vivo).
English: Therefore, the combination should be administered with caution, especially in the elderly.
Lithuanian: Taigi, minetus preparatus vartoti kartu reikia atsargiai, ypac senyviems pacientams.
English: Examples of drugs which are metabolised by CYP2C19 are diazepam, citalopram and imipramine.
Lithuanian: CYP2C19 metabolizuoja diazepama, citaloprama ir imipramina.
English: Caution should be exercised when combining celecoxib with warfarin and other oral anticoagulants (See 4.5).
Lithuanian: Pacientams, kartu vartojusiems varfarino, buvo sunkiu kraujavimo atveju. Celekoksiba kartu su varfarinu ir kitais geriamaisiais antikoaguliantais reikia vartoti atsargiai (žr. 4.5 skyriu).
English: Capsules 100 mg contain lactose monohydrate, sodium lauryl sulphate, povidone K30, croscarmellose sodium and magnesium stearate.
Lithuanian: Laktozes monohidratas, natrio laurilo sulfatas, povidonas K30, kroskarmeliozes natrio druska ir magnio stearatas.
English: Studies in animals (rats and rabbits) have shown reproductive toxicity, including malformations (see 4.3 and 5.3).
Lithuanian: Su gyvunais (žiurkemis ir triušiais) atlikti tyrimai rodo, kad preparatas daro toksini poveiki reprodukcijai, iskaitant apsigimimus (žr.
English: Reproductive system and breast disorders Very rare: menstrual disorder NOS
Lithuanian: Lytines sistemos ir kruties sutrikimai Labai reti: menesiniu ciklo sutrikimai NOS.
English: Approximately 7400 patients were treated with celecoxib in controlled trials and of those approximately 2300 have received it for 1 year or longer.
Lithuanian: Apie 2300 iš ju vartojo preparata vienerius metus arba ilgiau.
English: The pharmacokinetics of celecoxib has not been studied in patients with renal impairment but is unlikely to be markedly changed in these patients.
Lithuanian: Celekoksibo farmakokinetika organizme ligoniu, kuriems yra inkstu funkcijos sutrikimas, netirta, bet tiketina, kad ji labai pakinta.
English: Therefore, celecoxib should be used with caution in patients with history of cardiac failure, left ventricular dysfunction or hypertension, and in patients with pre-existing oedema from any other reason, since prostaglandin inhibition may result in deterioration of renal function and fluid retention.
Lithuanian: Rekomenduojama atsargiai celekoksibu gydyti pacientus, kuriems yra širdies nepakankamumas, hipertenzija, sutrikusi kairiojo skilvelio veikla, bei tiems, kuriems edema atsirado del bet kuriu kitu priežasciu, nes slopinant prostaglandinu sinteze, gali sutrikti inkstu funkcija ir organizme kauptis skysciai.
English: Anticoagulant activity should be monitored particularly in the first few days after initiating or changing the dose of celecoxib in patients receiving warfarin or other anticoagulants since these patients have an increased risk of bleeding complications.
Lithuanian: Rekomenduojama tirti, ypac pirmasias kelias dienas nuo gydymo celekoksibu pradžios, pacientu, kurie vartoja varfarina arba kitu antikoaguliantu, antikoaguliacini aktyvuma, nes padideja kraujavimo pavojus, bei keisti celekoksibo doze.
English: COX-2 is the isoform of the enzyme that has been shown to be induced by proinflammatory stimuli and has been postulated to be primarily responsible for the synthesis of prostanoid mediators of pain, inflammation, and fever.
Lithuanian: Izoforma COX-2 aktyvuoja uždegiminiai dirgikliai, ji pirmiausia skatina prostanoidiniu skausmo, uždegimo ir karšciavimo mediatoriu sinteze.
English: Compared to subjects with normal hepatic function, patients with mild hepatic impairment had a mean increase in Cmax of 53% and in AUC of 26% of celecoxib.
Lithuanian: Pacientu, kuriems yra nesunkus kepenu funkcijos sutrikimas, celekoksibo Cmax kraujo plazmoje 53%, o AUC 26% didesne, palyginti su susidarancia sveiku asmenu kraujyje.
English: Celecoxib is metabolised in the liver by hydroxylation, oxidation and some glucuronidation.
Lithuanian: Celekoksibas metabolizuojamas kepenyse hidroksilinimo, oksidacijos ir konjugacijos su gliukurono rugštimi budais.
English: During celecoxib treatment, the plasma concentrations of the CYP2D6 substrate dextromethorphan were increased by 136%.
Lithuanian: Vartojant celekoksiba, CYP2D6 metabolizuojamo dekstrometorfano koncentracija kraujo plazmoje padideja 136%.
English: Twenty-two percent of enrolled patients took concomitant low-dose acetylsalicylic acid (£325 mg/day),
Lithuanian: 22 procentai pacientu daugiausia širdies ir kraujagysliu sutrikimu profilaktikai kartu gere maža acetilsalicilo doze (=325 mg per para).